Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:2/7/2015
Start Date:October 2014
End Date:January 2017
Contact:Joy Zhu, MD, PhD
Email:joy@zenithepigenetics.com
Phone:650-387-7865

Use our guide to learn which trials are right for you!

Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia

The purpose of this study is to determine safety, tolerability, dose limiting toxicities
(DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory
lymphoproliferative malignancies (LPM) or relapsed/refractory acute myeloid leukemia (AML).


Inclusion Criteria:

Dose Escalation and Expansion Stages:

- ECOG performance status ≤ 1 for LPM patients, ≤ 2 for AML patients

- Age 18 years or older

- Adverse events (AEs), except for alopecia, from any previous treatments must have
recovered to eligibility levels from prior toxicity

- Adequate renal, hepatic and coagulation function, as specified per protocol

- Written informed consent granted prior to any study-specific screening procedures

LPM Patients:

- Histologically confirmed lymphoproliferative malignancy

- Have received prior protocol-specified disease-dependent prior treatments

- Have measurable disease

- Platelets ≥ 75,000/µL (≥50,000/µL if bone marrow involvement), absolute neutrophil
count (ANC) ≥ 1,000/ µL, and hemoglobin (Hgb) ≥ 8 g/dL

- Patients must have been off previous anticancer therapy for at least 3 weeks or 5
half-lives, whichever is longer, and the subject must have recovered to eligibility
levels from prior toxicity

AML:

- Refractory or relapsed AML patients, without curative intent, e.g., not a stem cell
transplant candidate

- Any prior chemotherapy must have been completed ≥ 2 weeks, any therapy with biologics
must have been completed ≥ 4 weeks prior to day 1 of study treatment, and the
participant must have recovered to eligibility levels from prior toxicity

- Blast count ≤ 10,000/µL prior to initiation of therapy

Exclusion Criteria

Dose Escalation and Expansion Stages:

- Prior exposure to a BET inhibitor

- Prior allogeneic hematopoietic cell transplant

- Chronic graft versus host disease

- Known, active fungal, bacterial, and/or viral infection

- Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

- Current subdural hematoma

- CNS or leptomeningeal metastases

- Requirement for medications or agents known to be sensitive CYP3A4 substrate drugs,
CYP3A4 substrate drugs with a narrow therapeutic range or to be strong
inhibitors/inducers of CYP3A4

- Requirement for immunosuppressive agents

- Evidence of significant cardiovascular disease or significant screening ECG
abnormalities

- Any medical conditions that, in the Investigator's opinion, would impose excessive
risk to the patient.

AML patients:

- Acute promyelocytic leukemia (APL)

- Chronic myeloid leukemia (CML) in blast crisis
We found this trial at
4
sites
1275 York Avenue
New York, New York 10065
212-639-2000
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private...
?
mi
from
New York, NY
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Springfield, OR
Click here to add this to my saved trials